医薬品CDMOの世界市場規模調査・予測：製品別、ワークフロー別、用途別、地域別分析、2023-2030年

世界の医薬品CDMO市場は、2022年に約1,369億4,000万米ドルと評価され、予測期間2023-2030年には6.1%以上の健全な成長率で成長すると予測されています。

医薬品CDMO（Contract Development and Manufacturing Organization）は、医薬品開発、製造、包装など、製薬業界にアウトソーシングサービスを提供する企業の一種です。CDMOは、医薬品開発や製造の特定の側面を引き受けるためのリソース、専門知識、設備を社内に持たない製薬会社に代わって業務を行います。

バイオ医薬品に対する需要の高まり、製造技術の向上、医薬品の開発・製造のアウトソーシング傾向など、多くの原因がこの拡大の原因となっています。医薬品CDMO市場は極めて重要な市場であり、その拡大はヘルスケア部門全体に利益をもたらすと予想されます。

医薬品CDMO市場は、業界の多額の研究開発費とバイオ医薬品のニーズ拡大の結果、今後数年間で成長すると予想されます。高齢化によって医薬品開発の新たな機会が生まれるため、医薬品市場は拡大する可能性が高いです。CDMOは医薬品開発・製造のアウトソーシングを通じて、製薬企業に費用対効果の高いソリューションと市場投入までの時間短縮を提供するため、製薬業界にとって不可欠な要素となっています。さらに、中国が有力なプレーヤーとして台頭しているバイオ医薬品業界の台頭は、今後さらに加速すると予想されます。製薬企業は継続的に研究開発に投資しており、それがバイオ医薬品の改良と新たな治療法や治療薬の開発に拍車をかけています。このパターンは今後も続くと予想され、上位15社の研究開発費は2020年に過去最高となります。世界の医薬品研究開発投資は、慢性疾患の増加やバイオシミラーの創出により増加し、市場の拡大を後押しすると予想されます。一般的に、医薬品CDMOの将来は明るく、製薬セクターにはいくつかの拡大の可能性があります。さらに、2021年には世界で1,000万人が死亡し、死因の第1位を占めるとされるがんの罹患率が世界的に上昇していることも、市場の拡大に拍車をかけています。革新的ながん治療薬に対する需要が増加し、製薬企業やCDMO企業にビジネスチャンスが生まれると予想されます。2020年には、医薬品部門におけるがん治療薬のパイプラインは約30％を占めると予想されています。毎年1,250万人以上が新たにがんと診断される中、がん治療分野は、発見と治療の進歩にもかかわらず、依然として困難で時間がかかり、進化し続けています。しかし、医薬品CDMOの高コストが、2023-2030年の予測期間を通じて市場の成長を阻害しています。

医薬品CDMOの世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。市場は異なる地域セグメントに分けられ、アジア太平洋地域は予測期間を通じて最も早いCAGR成長を遂げ、2022年には最大の市場シェアを獲得すると予想されます。APAC地域の市場拡大は、北米や欧州に比べて製造コストが低いことに起因しており、医薬品製造のアウトソーシング拠点として望ましいです。同地域の市場が拡大しているのは、大学付属の製薬研究ハブが存在し、多額の資金が集まっているためです。北米や欧州では有利な法律があり、製造コストが大幅に低いため、インドと中国が開発・製造受託機関の市場をリードしています。

本調査の目的は、近年のさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における業界の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

• 市場スナップショット
• 世界市場・セグメント別市場推計・予測、2020-2030年
  • 医薬品CDMO市場：地域別、2020-2030年
  • 医薬品CDMO市場：製品別、2020-2030年
  • 医薬品CDMO市場：ワークフロー別、2020-2030年
  • 医薬品CDMO市場：用途別、2020-2030年
• 主要動向
• 調査手法
• 調査前提条件

第2章 世界の医薬品CDMO市場の定義と範囲

• 調査目的
• 市場の定義と範囲
  • 業界の進化
  • 調査範囲
• 調査対象年
• 通貨換算レート

第3章 世界の医薬品CDMO市場力学

• 医薬品CDMO市場のインパクト分析（2020-2030年）
  • 市場促進要因
    • バイオ医薬品需要の増加
    • 世界のがん患者の増加
  • 市場の課題
    • 医薬品CDMOの高コスト
  • 市場機会
    • 製造技術の進歩

第4章 世界の医薬品CDMO市場の産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォース影響分析
• PEST分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 環境
  • 法律
• 主な投資機会
• 主要成功戦略
• COVID-19影響分析
• 破壊的動向
• 業界専門家の視点
• アナリストの結論・提言

第5章 医薬品CDMOの世界市場：製品別

• 市場スナップショット
• 医薬品CDMOの世界市場：製品別、業績別、ポテンシャル分析
• 医薬品CDMOの世界市場：製品別推定・予測、2020-2030年
• 医薬品CDMO市場のサブセグメント分析
  • 原薬（API）
  • 医薬品

第6章 医薬品CDMOの世界市場：ワークフロー別

• 市場スナップショット
• 医薬品CDMOの世界市場：ワークフロー別、実績 - ポテンシャル分析
• 医薬品CDMOの世界市場：ワークフロー別推計・予測、2020-2030年
• 医薬品CDMO市場のサブセグメント分析
  • 臨床
  • 商業

第7章 医薬品CDMOの世界市場：用途別

• 市場スナップショット
• 医薬品CDMOの世界市場：用途別実績-ポテンシャル分析
• 医薬品CDMOの世界市場：用途別推定・予測、2020-2030年
• 医薬品CDMO市場のサブセグメント分析
  • 腫瘍
  • ホルモン
  • 緑内障
  • 心血管疾患
  • 糖尿病
  • その他

第8章 医薬品CDMOの世界市場、地域分析

• 主要国
• 主な新興国
• 医薬品CDMO市場の地域別市場スナップショット
• 北米
  • 米国
    • 製品別の推定・予測、2020-2030年
    • ワークフローの推定・予測、2020-2030年
    • 用途の推定・予測、2020-2030年
  • カナダ
• 欧州の医薬品CDMO市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋の医薬品CDMO市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカの医薬品CDMO市場スナップショット
  • ブラジル
  • メキシコ
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • その他中東とアフリカ

第9章 競合情報

• 主要企業のSWOT分析
• 主要市場戦略
• 企業プロファイル
  • Bushu Pharmaceuticals Ltd.
    • 主要情報
    • 概要
    • 財務（データの入手可能性によります）
    • 製品概要
    • 最近の動向
  • Nipro Corporation
  • Thermo Fisher Scientific Inc.
  • Samsung Biologics
  • Laboratory Corporation of America Holdings
  • Siegfried Holding Ag
  • Catalent, Inc
  • Lonza Group AG
  • Recipharm Ab
  • Piramal Pharma Solutions

第10章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • 検証
  • 出版
• 調査属性
• 調査前提条件

LIST OF TABLES

• TABLE 1. Global Pharmaceutical CDMO Market, report scope
• TABLE 2. Global Pharmaceutical CDMO Market estimates & forecasts by Region 2020-2030 (USD Billion)
• TABLE 3. Global Pharmaceutical CDMO Market estimates & forecasts by Product 2020-2030 (USD Billion)
• TABLE 4. Global Pharmaceutical CDMO Market estimates & forecasts by Workflow 2020-2030 (USD Billion)
• TABLE 5. Global Pharmaceutical CDMO Market estimates & forecasts by Application 2020-2030 (USD Billion)
• TABLE 6. Global Pharmaceutical CDMO Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 7. Global Pharmaceutical CDMO Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 8. Global Pharmaceutical CDMO Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 9. Global Pharmaceutical CDMO Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 10. Global Pharmaceutical CDMO Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 11. Global Pharmaceutical CDMO Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 12. Global Pharmaceutical CDMO Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 13. Global Pharmaceutical CDMO Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 14. Global Pharmaceutical CDMO Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 15. Global Pharmaceutical CDMO Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 16. U.S. Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 17. U.S. Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 18. U.S. Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 19. Canada Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 20. Canada Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 21. Canada Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 22. UK Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 23. UK Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 24. UK Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 25. Germany Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 26. Germany Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 27. Germany Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 28. France Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 29. France Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 30. France Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 31. Italy Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 32. Italy Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 33. Italy Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 34. Spain Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 35. Spain Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 36. Spain Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 37. RoE Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 38. RoE Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 39. RoE Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 40. China Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 41. China Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 42. China Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 43. India Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 44. India Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 45. India Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 46. Japan Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 47. Japan Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 48. Japan Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 49. South Korea Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 50. South Korea Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 51. South Korea Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 52. Australia Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 53. Australia Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 54. Australia Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 55. RoAPAC Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 56. RoAPAC Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 57. RoAPAC Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 58. Brazil Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 59. Brazil Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 60. Brazil Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 61. Mexico Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 62. Mexico Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 63. Mexico Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 64. RoLA Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 65. RoLA Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 66. RoLA Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 67. Saudi Arabia Pharmaceutical CDMO Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 68. South Africa Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 69. RoMEA Pharmaceutical CDMO Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 70. List of secondary sources, used in the study of global Pharmaceutical CDMO Market
• TABLE 71. List of primary sources, used in the study of global Pharmaceutical CDMO Market
• TABLE 72. Years considered for the study
• TABLE 73. Exchange rates considered

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

• FIG 1. Global Pharmaceutical CDMO Market, research methodology
• FIG 2. Global Pharmaceutical CDMO Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Pharmaceutical CDMO Market, key trends 2022
• FIG 5. Global Pharmaceutical CDMO Market, growth prospects 2023-2030
• FIG 6. Global Pharmaceutical CDMO Market, porters 5 force model
• FIG 7. Global Pharmaceutical CDMO Market, pest analysis
• FIG 8. Global Pharmaceutical CDMO Market, value chain analysis
• FIG 9. Global Pharmaceutical CDMO Market by segment, 2020 & 2030 (USD Billion)
• FIG 10. Global Pharmaceutical CDMO Market by segment, 2020 & 2030 (USD Billion)
• FIG 11. Global Pharmaceutical CDMO Market by segment, 2020 & 2030 (USD Billion)
• FIG 12. Global Pharmaceutical CDMO Market by segment, 2020 & 2030 (USD Billion)
• FIG 13. Global Pharmaceutical CDMO Market by segment, 2020 & 2030 (USD Billion)
• FIG 14. Global Pharmaceutical CDMO Market, regional snapshot 2020 & 2030
• FIG 15. North America Pharmaceutical CDMO Market 2020 & 2030 (USD Billion)
• FIG 16. Europe Pharmaceutical CDMO Market 2020 & 2030 (USD Billion)
• FIG 17. Asia pacific Pharmaceutical CDMO Market 2020 & 2030 (USD Billion)
• FIG 18. Latin America Pharmaceutical CDMO Market 2020 & 2030 (USD Billion)
• FIG 19. Middle East & Africa Pharmaceutical CDMO Market 2020 & 2030 (USD Billion)

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

Global Pharmaceutical CDMO Market is valued approximately at USD 136.94 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.1% over the forecast period 2023-2030. Pharmaceutical CDMO (Contract Development and Manufacturing Organization) is a type of company that provides outsourced services for the pharmaceutical industry, including drug development, manufacturing, and packaging. CDMOs work on behalf of pharmaceutical companies that do not have the internal resources, expertise, or facilities to undertake certain aspects of drug development or manufacturing.

Numerous causes, such as the rising demand for biopharmaceuticals, improvements in manufacturing technology, and the tendency to outsource medication development and manufacture, are responsible for the expansion. The pharmaceutical industry's contract development and manufacturing organization (CDMO) market is a crucial one, and its expansion is anticipated to benefit the entire healthcare sector.

The pharmaceutical CDMO market is expected to grow in the future years as a result of the industry's significant R&D expenditures and the expanding need for biopharmaceuticals. The market for medicines is likely to expand as the ageing population creates new opportunities for drug development. Since they provide pharmaceutical businesses with cost-effective solutions and a shorter time to market through the outsourcing of drug development and production, CDMOs are an essential component of the pharmaceutical industry. In addition, the rise of the biopharma industry, with China emerging as a prominent player, is anticipated to accelerate. Pharmaceutical businesses continually invest in R&D, which is fueling improvements in biopharmaceuticals and the development of fresh therapies and cures. It is anticipated that this pattern would continue, with the top 15 businesses spending a record amount on R&D in 2020. Global pharmaceutical R&D investment is anticipated to increase due to the rising prevalence of chronic diseases and the creation of biosimilars, thus boosting the market's expansion. In general, the pharmaceutical CDMO future is bright, with several expansion potential opening in the pharmaceutical sector. Additionally, the market is expanding due to the rising incidence of cancer worldwide, which will account for 10 million deaths worldwide in 2021 and be the leading cause of death. It is anticipated that there would be an increase in the demand for innovative cancer therapies, creating opportunities for pharmaceutical and CDMO businesses. In 2020, it is anticipated that the pipeline for oncology medicines in the pharmaceutical sector would make up about 30% of it. With more than 12.5 million new instances of cancer diagnosed each year, the oncology sector is still difficult, time-consuming, and evolving despite the advances in detection and treatment. However, the high cost of Pharmaceutical CDMO stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Pharmaceutical CDMO Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. The market is divided into different geographic segments, with Asia Pacific expected to have the quickest CAGR growth throughout the projected period and have the greatest market share in 2022. The APAC region's market expansion can be attributable to lower manufacturing costs than those in North America and Europe, which makes it a desirable outsourcing hub for the creation of pharmaceuticals. The region's market is expanding due to the presence of university-affiliated pharmaceutical research hubs and significant funding. Due to favorable legislation and much lower production costs in North America and Europe, India and China are leading the market for contract development and manufacturing organizations.

Major market players included in this report are:

• Bushu Pharmaceuticals Ltd.
• Nipro Corporation
• Thermo Fisher Scientific Inc.
• Samsung Biologics
• Laboratory Corporation of America Holdings
• Siegfried Holding Ag
• Catalent, Inc
• Lonza Group AG
• Recipharm Ab
• Piramal Pharma Solutions

Recent Developments in the Market:

• In 2020, WuXi AppTec, a Chinese-based Pharmaceutical CDMO, announced the launch of a new digital technology platform to enable end-to-end supply chain management for the pharmaceutical industry.
• Some Pharmaceutical CDMOs are adopting sustainability initiatives to reduce their environmental impact. In 2021, Lonza announced its commitment to achieve net-zero greenhouse gas emissions by 2050 and to reduce its carbon footprint by 50% by 2030.

Global Pharmaceutical CDMO Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Product, Workflow, Application, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

• API
• Drug

By Workflow:

• Clinical
• Commercial

By Application:

• Oncology
• Hormonal
• Glaucoma
• Cardiovascular Disease
• Diabetes
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Pharmaceutical CDMO Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Pharmaceutical CDMO Market, by Product, 2020-2030 (USD Billion)
  • 1.2.3. Pharmaceutical CDMO Market, by Workflow, 2020-2030 (USD Billion)
  • 1.2.4. Pharmaceutical CDMO Market, by Application, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Pharmaceutical CDMO Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Pharmaceutical CDMO Market Dynamics

• 3.1. Pharmaceutical CDMO Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing demand for biopharmaceuticals
    • 3.1.1.2. Increasing Cases of Cancer across the Globe
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Pharmaceutical CDMO
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Technological advancements in manufacturing

Chapter 4. Global Pharmaceutical CDMO Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Pharmaceutical CDMO Market, by Product

• 5.1. Market Snapshot
• 5.2. Global Pharmaceutical CDMO Market by Product, Performance - Potential Analysis
• 5.3. Global Pharmaceutical CDMO Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
• 5.4. Pharmaceutical CDMO Market, Sub Segment Analysis
  • 5.4.1. API
  • 5.4.2. Drug

Chapter 6. Global Pharmaceutical CDMO Market, by Workflow

• 6.1. Market Snapshot
• 6.2. Global Pharmaceutical CDMO Market by Workflow, Performance - Potential Analysis
• 6.3. Global Pharmaceutical CDMO Market Estimates & Forecasts by Workflow 2020-2030 (USD Billion)
• 6.4. Pharmaceutical CDMO Market, Sub Segment Analysis
  • 6.4.1. Clinical
  • 6.4.2. Commercial

Chapter 7. Global Pharmaceutical CDMO Market, by Application

• 7.1. Market Snapshot
• 7.2. Global Pharmaceutical CDMO Market by Application, Performance - Potential Analysis
• 7.3. Global Pharmaceutical CDMO Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 7.4. Pharmaceutical CDMO Market, Sub Segment Analysis
  • 7.4.1. Oncology
  • 7.4.2. Hormonal
  • 7.4.3. Glaucoma
  • 7.4.4. Cardiovascular Disease
  • 7.4.5. Diabetes
  • 7.4.6. Others

Chapter 8. Global Pharmaceutical CDMO Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Pharmaceutical CDMO Market, Regional Market Snapshot
• 8.4. North America Pharmaceutical CDMO Market
  • 8.4.1. U.S. Pharmaceutical CDMO Market
    • 8.4.1.1. Product breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Workflow breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. Application breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Pharmaceutical CDMO Market
• 8.5. Europe Pharmaceutical CDMO Market Snapshot
  • 8.5.1. U.K. Pharmaceutical CDMO Market
  • 8.5.2. Germany Pharmaceutical CDMO Market
  • 8.5.3. France Pharmaceutical CDMO Market
  • 8.5.4. Spain Pharmaceutical CDMO Market
  • 8.5.5. Italy Pharmaceutical CDMO Market
  • 8.5.6. Rest of Europe Pharmaceutical CDMO Market
• 8.6. Asia-Pacific Pharmaceutical CDMO Market Snapshot
  • 8.6.1. China Pharmaceutical CDMO Market
  • 8.6.2. India Pharmaceutical CDMO Market
  • 8.6.3. Japan Pharmaceutical CDMO Market
  • 8.6.4. Australia Pharmaceutical CDMO Market
  • 8.6.5. South Korea Pharmaceutical CDMO Market
  • 8.6.6. Rest of Asia Pacific Pharmaceutical CDMO Market
• 8.7. Latin America Pharmaceutical CDMO Market Snapshot
  • 8.7.1. Brazil Pharmaceutical CDMO Market
  • 8.7.2. Mexico Pharmaceutical CDMO Market
• 8.8. Middle East & Africa Pharmaceutical CDMO Market
  • 8.8.1. Saudi Arabia Pharmaceutical CDMO Market
  • 8.8.2. South Africa Pharmaceutical CDMO Market
  • 8.8.3. Rest of Middle East & Africa Pharmaceutical CDMO Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Bushu Pharmaceuticals Ltd.
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Nipro Corporation
  • 9.3.3. Thermo Fisher Scientific Inc.
  • 9.3.4. Samsung Biologics
  • 9.3.5. Laboratory Corporation of America Holdings
  • 9.3.6. Siegfried Holding Ag
  • 9.3.7. Catalent, Inc
  • 9.3.8. Lonza Group AG
  • 9.3.9. Recipharm Ab
  • 9.3.10. Piramal Pharma Solutions

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption